IMMUNIC, INC.

IMUXSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1280776

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	$80.0M	$83.2M	$71.3M	$61.1M	$38.6M
Operating Expenses	$98.1M	$99.2M	$119.5M	$91.7M	$9.0M
Operating Income (Loss)	-$98.1M	-$99.2M	-$119.5M	-$91.7M	-$49.0M
Interest Expense	—	—	—	—	—
Nonoperating Income (Expense)	-$2.5M	$5.6M	-$919.0K	-$1.3M	$5.0M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	—	—	—	—	—
Income Tax Expense (Benefit)	$0.00	—	—	—	—
Net Income (Loss) Attributable to Parent	-$100.5M	-$93.6M	-$120.4M	-$92.9M	-$8.5M
Earnings Per Share, Basic	-$1.00	-$2.11	-$3.78	-$3.93	-$0.79
Earnings Per Share, Diluted	-$1.00	-$2.11	-$3.78	-$3.93	-$0.79

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$40.9M	$54.3M	$127.8M	$139.1M	$167.9M
Assets, Current	$39.3M	$52.5M	$125.9M	$105.0M	$133.7M
Cash and Cash Equivalents, at Carrying Value	$35.7M	$46.7M	$106.7M	$86.9M	$127.5M
Liabilities	$22.4M	$25.4M	$14.1M	$12.0M	$9.1M
Liabilities, Current	$22.2M	$24.7M	$13.1M	$11.4M	$8.4M
Accounts Payable, Current	$7.8M	$5.1M	$4.3M	$3.7M	$3.7M
Stockholders' Equity Attributable to Parent	$28.9M	$113.7M	$127.1M	$158.8M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$84.8M	-$70.8M	-$65.1M	-$83.2M	-$46.1M
Net Cash Provided by (Used in) Investing Activities	-$264.0K	$9.5M	-$9.7M	-$67.0K	-$146.0K
Net Cash Provided by (Used in) Financing Activities	$74.5M	$1.0M	$95.8M	$42.8M	$144.4M
Payments to Acquire Property, Plant, and Equipment	$264.0K	$334.0K	$112.0K	$67.0K	$146.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)